75 research outputs found
Th17 Cytokines in Autoimmunity
The human immune system is composed of several organs and many diff erent cell types that
protect the body against any parti cle that is not part of the body, the non-self. Mostly, these
will be invading pathogens or cancer cells. The immune system can be divided into two main
components: an innate component and an adapti ve component (fi gure 1). These two components
do not operate separately, but are in fact closely linked and depend upon each other.
When the body is invaded by pathogens, cells of the innate immune system are quickly
acti vated to limit the infecti on. However, they are not specifi c for one type of anti gen; rather
they respond to epitopes present on many diff erent pathogens, like pepti doglycans and
lipopolysaccharides, which have been strongly conserved during evoluti on. Contrary to the
innate immune system, cells of the adapti ve immune system are highly specifi c for one parti cular
epitope or anti gen. Development of this specifi c response takes several days, but leads to a
much stronger and long lasti ng immune response. Furthermore, the high specifi city provides
the possibility of developing memory cells that will be able to respond more quickly if a similar
pathogen invades the body again
B Cell Signaling and Activation in Autoimmunity
Autoreactive B cells play a key role in the initiation or aggravation of many systemic and tissue-specific autoimmune disorders [...
Aberrant B Cell Signaling in Autoimmune Diseases
Aberrant B cell signaling plays a critical in role in various systemic and organ-specific autoimmune diseases. This is supported by genetic evidence by many functional studies in B cells from patients or specific animal models and by the observed efficacy of small-molecule inhibitors. In this review, we first discuss key signal transduction pathways downstream of the B cell receptor (BCR) that ensure that autoreactive B cells are removed from the repertoire or functionally silenced. We provide an overview of aberrant BCR signaling that is associated with inappropriate B cell repertoire selection and activation or survival of peripheral B cell populations and plasma cells, finally leading to autoantibody formation. Next to BCR signaling, abnormalities in other signal transduction pathways have been implicated in autoimmune disease. These include reduced activity of several phosphates that are downstream of co-inhibitory receptors on B cells and increased levels of BAFF and APRIL, which support survival of B cells and plasma cells. Importantly, pathogenic synergy of the BCR and Toll-like receptors (TLR), which can be activated by endogenous ligands, such as self-nucleic acids, has been shown to enhance autoimmunity. Finally, we will briefly discuss therapeutic strategies for autoimmune disease based on interfering with signal transduction in B cells
Response to 'T-helper 17 cell cytokines and interferon type I: Partners in crime in systemic lupus erythematosus?' - Authors' reply
IL-23 Dependent and Independent Stages of Experimental Arthritis: No Clinical Effect of Therapeutic IL-23p19 Inhibition in Collagen-induced Arthritis
IL-23p19 deficient mice have revealed a critical role of IL-23 in the development of experimental autoimmune diseases, such as collagen-induced arthritis (CIA). Neutralizing IL-23 after onset of CIA in rats has been shown to reduce paw volume, but the effect on synovial inflammation and the immunological autoimmune response is not clear. In this study, we examined the role of IL-23 at different stages of CIA and during T cell memory mediated flare-up arthritis with focus on changes in B cell activity and Th1/Th17 modulation. Anti-IL-23p19 antibody (anti-IL23p19) treatment, starting 15 days after the type II collagen (CII)-immunization but before clinical signs of disease onset, significantly suppressed the severity of CIA. This was accompanied with significantly lower CII-specific IgG1 levels and lower IgG2a levels in the anti-IL-23p19 treated mice compared to the control group. Importantly, neutralizing IL-23 after the first signs of CIA did not ameliorate the disease. This was in contrast to arthritic mice that underwent an arthritis flare-up since a significantly lower disease score was observed in the IL-23p19 treated mice compared to the control group, accompanied by lower synovial IL-17A and IL-22 expression in the knee joints of these mice. These data show IL-23-dependent and IL-23-independent stages during autoimmune CIA. Furthermore, the memory T cell mediated flare-up arthritis is IL-23-mediated. These data suggest that specific neutralization of IL-23p19 after onset of autoimmune arthritis may not be beneficial as a therapeutic therapy for patients with rheumatoid arthritis (RA). However, T cell mediated arthritis relapses in patients with RA might be controlled by anti-IL-23p19 treatment
Th17 cells in primary Sjogren's syndrome:Pathogenicity and plasticity
Th17 cells play an important physiological role at mucosal barriers, and are involved in inflammatory responses to pathogens. Th17 cells and their signature cytokine IL-17 are also present in salivary gland lesions of primary Sjogren's syndrome (pSS) patients and can be elevated in their peripheral blood. In pSS patients, clear correlations between increased Th17 cell activity and symptoms of the disease have not been found, but Th17 cells may contribute to disease progression, for example by supporting autoreactive B cell responses. In mouse models of pSS, Th17 cells play an important role in pathogenesis, particularly at disease onset, when there is a disturbed balance between T effector and T regulatory cells. Studying the pathogenicity of Th17 cells in humans is complicated due to the plasticity of this cell subset, allowing them to obtain different effector functions depending on the local environment. Th17 cells can develop towards Th17.1 cells, producing both IL-17 and IFN-gamma, or even towards Th1-like cells producing IFN-gamma in the absence of IL-17. These effector subsets may be more pathogenic than bona fide Th17 cells. Co-expression of IFN-y by Th17 cells has been shown to promote chronic inflammation in several auto immune diseases and may also contribute to pSS pathogenesis. In line with the noticeable role of IL-17 in pSS mouse models, interference with Th17 cell generation, recruitment or effector functions (e.g. IL-17 inhibition) can prevent or ameliorate disease in these models. Therapies targeting Th17 cells or IL-17 have not been tested so far in pSS patients, although treatment with rituximab seems to lower local and systemic IL-17 protein levels, and to a lesser extent also chemokine receptor-defined Th17 cells. In this review we discuss current knowledge of pathogenicity and plasticity of Th17 cells in human pSS and murine models of pSS. We postulate that plasticity towards Th17.1 cells in pSS may enhance pathogenicity of Th17 cells at the main target sites of the disease, i.e. salivary and lacrimal glands. (C) 2017 The Authors. Published by Elsevier Ltd
Decreased BAFF Receptor Expression and Unaltered B Cell Receptor Signaling in Circulating B Cells from Primary Sjogren's Syndrome Patients at Diagnosis
Animal models of autoimmunity and human genetic association studies indicate that the dysregulation of B-cell receptor (BCR) signaling is an important driver of autoimmunity. We previously showed that in circulating B cells from primary Sjogren's syndrome (pSS) patients with high systemic disease activity, protein expression of the BCR signaling molecule Bruton's tyrosine kinase (BTK) was increased and correlated with T-cell infiltration in the target organ. We hypothesized that these alterations could be driven by increased B-cell activating factor (BAFF) levels in pSS. Here, we investigated whether altered BCR signaling was already present at diagnosis and distinguished pSS from non-SS sicca patients. Using (phospho-)flow cytometry, we quantified the phosphorylation of BCR signaling molecules, and investigated BTK and BAFF receptor (BAFFR) expression in circulating B cell subsets in an inception cohort of non-SS sicca and pSS patients, as well as healthy controls (HCs). We found that both BTK protein levels and BCR signaling activity were comparable among groups. Interestingly, BAFFR expression was significantly downregulated in pSS, but not in non-SS sicca patients, compared with HCs, and correlated with pSS-associated alterations in B cell subsets. These data indicate reduced BAFFR expression as a possible sign of early B cell involvement and a diagnostic marker for pSS
Aberrant B cell receptor signaling in naïve B cells from patients with idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal disease in which an impaired healing response to recurrent micro-injuries is thought to lead to fibrosis. Recent findings hint at a role for B cells and autoimmunity in IPF pathogenesis. We previously reported that circulating B cells from a fraction of patients, compared with healthy controls, express increased levels of the signaling molecule Bruton’s tyrosine kinase (BTK). However, it remains unclear whether B cell receptor (BCR) signaling is altered in IPF. Here, we show that the response to BCR stimulation is enhanced in peripheral blood B cells from treatment-naïve IPF patients. We observed increased anti-immunoglobulin-induced phosphorylation of BTK and its substrate phospholipase Cγ2 (PLCγ2) in naïve but not in memory B cells of patients with IPF. In naïve B cells of IPF patients enhanced BCR signaling correlated with surface expression of transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI) but not B cell activating factor receptor (BAFFR), both of which provide pro-survival signals. Interestingly, treatment of IPF patients with nintedanib, a tyrosine kinase inhibitor with anti-fibrotic and anti-inflammatory activity, induced substantial changes in BCR signaling. These findings support the involvement of B cells in IPF pathogenesis and suggest that targeting BCR signaling has potential value as a treatment option.</p
Increased proportions of circulating PD-1<sup>+</sup> CD4<sup>+</sup> memory T cells and PD-1<sup>+</sup> regulatory T cells associate with good response to prednisone in pulmonary sarcoidosis
Background: The treatment response to corticosteroids in patients with sarcoidosis is highly variable. CD4+ T cells are central in sarcoid pathogenesis and their phenotype in peripheral blood (PB) associates with disease course. We hypothesized that the phenotype of circulating T cells in patients with sarcoidosis may correlate with the response to prednisone treatment. Therefore, we aimed to correlate frequencies and phenotypes of circulating T cells at baseline with the pulmonary function response at 3 and 12 months during prednisone treatment in patients with pulmonary sarcoidosis. Methods:We used multi-color flow cytometry to quantify activation marker expression on PB T cell populations in 22 treatment-naïve patients and 21 healthy controls (HCs). Pulmonary function tests at baseline, 3 and 12 months were used to measure treatment effect. Results: Patients with sarcoidosis showed an absolute forced vital capacity (FVC) increase of 14.2% predicted (± 10.6, p < 0.0001) between baseline and 3 months. Good response to prednisone (defined as absolute FVC increase of ≥ 10% predicted) was observed in 12 patients. CD4+ memory T cells and regulatory T cells from patients with sarcoidosis displayed an aberrant phenotype at baseline, compared to HCs. Good responders at 3 months had significantly increased baseline proportions of PD-1+CD4+ memory T cells and PD-1+ regulatory T cells, compared to poor responders and HCs. Moreover, decreased fractions of CD25+ cells and increased fractions of PD-1+ cells within the CD4+ memory T cell population correlated with ≥ 10% FVC increase at 12 months. During treatment, the aberrantly activated phenotype of memory and regulatory T cells reversed. Conclusions: Increased proportions of circulating PD-1+CD4+ memory T cells and PD-1+ regulatory T cells and decreased proportions of CD25+CD4+ memory T cells associate with good FVC response to prednisone in pulmonary sarcoidosis, representing promising new blood biomarkers for prednisone efficacy. Trial registration: NL44805.078.13</p
Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease
Bruton’s tyrosine kinase (Btk) is a signaling molecule involved in development and
activation of B cells through B-cell receptor (BCR) and Toll-like receptor (TLR)
signaling. We have previously shown that transgenic mice that overexpress human Btk
under the control of the CD19 promoter (CD19-hBtk) display spontaneous germinal
center formation, increased cytokine production, anti-nuclear autoantibodies (ANAs),
and systemic autoimsmune disease upon aging. As TLR and BCR signaling are
both implicated in autoimmunity, we studied their impact on splenic B cells. Using
phosphoflow cytometry, we observed that phosphorylation of ribosomal protein S6, a
downstream Akt target, was increased in CD19-hBtk B cells following BCR stimulation
or combined BCR/TLR stimulation, when compared with wild-type (WT) B cells. The
CD19-hBtk transgene enhanced BCR-induced B cell survival and proliferation, but had
an opposite effect following TLR9 or combined BCR/TLR9 stimulation. Although the
expression of TLR9 was reduced in CD19-hBtk B cells compared to WT B cells, a
synergistic effect of TLR9 and BCR stimulation on the induction of CD25 and CD80 was
observed in CD19-hBtk B cells. In splenic follicular (Fol) and marginal zone (MZ) B cells
from aging CD19-hBtk mice BCR signaling stimulated in vitro IL-10 production in synergy
with TLR4 and particularly TLR9 stimulation, but not with TLR3 and TLR7. The enhanced
capacity of CD19-hBtk Fol B cells to produce the pro-inflammatory cytokines IFNγ and
IL-6 compared with WT B cells was however not further increased following in vitro BCR
or TLR9 stimulation. Finally, we used crosses with mice deficient for the TLR-associated
molecule myeloid differentiation primary response 88 (MyD88) to show that TLR signaling
was crucial for spontaneous formation of germinal centers, increased IFNγ, and IL-6
production by B cells and anti-nuclear autoantibody induction in CD19-hBtk mice. Taken
together, we conclude that high Btk expression does not only increase B cell survival
following BCR stimulation, but also renders B cells more sensitive to TLR stimulation,
resulting in increased expression of CD80, and IL-10 in activated B cells. Although
BCR-TLR interplay is complex, our findings show that both signaling pathways are crucial
for the development of pathology in a Btk-dependent model for systemic autoimmune
disease
- …